Key Takeaways
- Federal regulators sent ImmunityBio a warning letter after determining a television advertisement and podcast episode contained illegal promotional claims about ANKTIVA, its bladder cancer treatment
- The marketing materials falsely implied ANKTIVA could address all cancer types — when regulatory approval exists only for one specific bladder cancer indication used with BCG treatment
- The FDA specifically named CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong as participants in the regulatory violations
- This represents ImmunityBio’s third regulatory notification regarding promotional compliance problems, following prior communications in September 2025 and January 2026
- ImmunityBio must submit a corrective action plan within 15 business days or potentially face enforcement proceedings
Shares of ImmunityBio plummeted on Tuesday following federal regulators’ determination that the company violated pharmaceutical advertising laws through a television commercial and podcast episode that grossly misrepresented ANKTIVA’s authorized medical applications, representing the biotech firm’s third promotional compliance failure.
$IBRX Receives Warning from FDA
My POV:
The FDA does not like the public pressure campaign Dr Pat is running.
Relevant text below:
The podcast originally aired on The Sean Spicer Show on January 19, 2026, and can also be accessed through ImmunityBio’s website.2 The FDA Bad…
— S&J Investments (@SJCapitalInvest) March 24, 2026
The FDA’s Office of Prescription Drug Promotion delivered a formal warning letter to ImmunityBio regarding a broadcast advertisement and a podcast episode entitled “Is the FDA BLOCKING Life Saving Cancer Treatments?” Regulators concluded both promotional vehicles violated federal pharmaceutical marketing statutes.
The fundamental violation centered on treatment scope misrepresentation. ANKTIVA holds regulatory clearance for a narrowly defined therapeutic application: treatment of adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer featuring carcinoma in situ, either with or without papillary tumors present, delivered via intravesical administration in combination with BCG immunotherapy.
The challenged promotional content dramatically exceeded these boundaries. The materials suggested ANKTIVA possessed capability to “treat all cancers,” could serve as a preventative measure for individuals with radiation exposure, and functioned as a standalone single-injection therapy. Federal regulators noted none of these assertions have clinical evidence support or regulatory authorization.
Both CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong made personal appearances in the contested materials and received direct citation in the FDA’s enforcement correspondence.
Regulators determined the promotional content misbranded ANKTIVA, rendering the drug’s commercial distribution a violation of the Federal Food, Drug, and Cosmetic Act.
A Pattern of Promotional Violations
This enforcement action represents a continuation of regulatory oversight for ImmunityBio. The FDA had dispatched untitled letters during September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional compliance deficiencies.
Tuesday’s correspondence constitutes the third regulatory communication — and carries significantly greater enforcement implications. FDA warning letters possess substantially more regulatory authority than untitled letters and demonstrate the agency’s intensifying compliance concerns.
The FDA additionally cited ImmunityBio for inadequate risk information presentation within the promotional materials and for excluding critical details regarding the drug’s authorized therapeutic indication.
The podcast episode also violated submission requirements, having never been provided to the FDA upon initial publication, representing an additional regulatory compliance failure.
Investor Response
IBRX shares declined approximately 15% to 21% on Tuesday, with certain trading platforms documenting intraday losses reaching 21% during morning session activity.
ImmunityBio now faces a 15 business day deadline to provide the FDA with written correspondence detailing a comprehensive remediation strategy addressing the identified violations.
The biotechnology company must additionally develop and execute corrective communication campaigns specifically directed toward audiences exposed to the misleading promotional content.
The FDA cautioned that inadequate corrective measures could trigger formal legal enforcement actions.
